Groowe Groowe / Newsroom / GILD
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

GILD News

Gilead Sciences Inc

Form 8-K

sec.gov
TENX LNSR BCRX MRK GILD

FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)

businesswire.com
MRK GILD

Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight

globenewswire.com
AZN CRSP NKTR INCY IPHA ABBV BIIB ALKS IMVT CLRB IMPP REGN THO AUTL KYMR CBIO GILD

Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda

globenewswire.com
MRK BMY GILD TAK

AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL USA - English USA - English

prnewswire.com
MRK GSK GILD

AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL USA - English USA - English

prnewswire.com
MRK GSK GILD

Form 8-K

sec.gov
RCUS GILD

New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore

prnewswire.com
GILD

U.S. Chamber Discusses How Medical Breakthroughs Are Extending Lives and Strengthening the Economy with YourUpdateTV

globenewswire.com
MRK PFE JNJ BMY GILD LLY AMGN REGN ABBV BIIB

Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026

prnewswire.com
GILD